Literature DB >> 1530664

Oxidative damage to lipids and alpha 1-antiproteinase by phenylbutazone in the presence of haem proteins: protection by ascorbic acid.

P J Evans1, R Cecchini, B Halliwell.   

Abstract

Phenylbutazone is an anti-inflammatory drug with numerous side-effects that restrict its clinical use. In the presence of myoglobin, or of haemoglobin plus H2O2, phenylbutazone accelerates the peroxidation of lipids (arachidonic acid and rat liver microsomes) and causes the inactivation of alpha-antiproteinase, so that this protein can no longer inhibit elastase. We propose that haem proteins oxidize phenylbutazone into a damaging free radical. Ascorbic acid inhibits these pro-oxidant actions of phenylbutazone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530664     DOI: 10.1016/0006-2952(92)90131-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases.

Authors:  S Basu; M Whiteman; D L Mattey; B Halliwell
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Protection against peroxynitrite dependent tyrosine nitration and alpha 1-antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline.

Authors:  M Whiteman; H Kaur; B Halliwell
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

3.  Hydroxyl radical generation by rheumatoid blood and knee joint synovial fluid.

Authors:  H Kaur; S E Edmonds; D R Blake; B Halliwell
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

4.  Protective effect of seminal plasma proteins on the degradation of ascorbic acid.

Authors:  L Liu; K Dabrowski; A Ciereszko
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

5.  Synthesis and Pharmacochemistry of New Pleiotropic Pyrrolyl Derivatives.

Authors:  Markella Konstantinidou; Alice Gkermani; Dimitra Hadjipavlou-Litina
Journal:  Molecules       Date:  2015-09-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.